Related references
Note: Only part of the references are listed.Advances in non-invasive drug delivery for atherosclerotic heart disease
Raul C. Maranhao et al.
EXPERT OPINION ON DRUG DELIVERY (2015)
Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation
Jun Tang et al.
SCIENCE ADVANCES (2015)
Innate Immune System Cells in Atherosclerosis
Luis Chavez-Sanchez et al.
ARCHIVES OF MEDICAL RESEARCH (2014)
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Nanomedicine-based strategies for treatment of atherosclerosis
Maximilian Schiener et al.
TRENDS IN MOLECULAR MEDICINE (2014)
Anti-Atherogenic Effects of Methotrexate Carried by a Lipid Nanoemulsion That Binds to LDL Receptors in Cholesterol-fed Rabbits
Adriana Bulgarelli et al.
CARDIOVASCULAR DRUGS AND THERAPY (2013)
Foam cells in atherosclerosis
Xiao-Hua Yu et al.
CLINICA CHIMICA ACTA (2013)
Local proliferation dominates lesional macrophage accumulation in atherosclerosis
Clinton S. Robbins et al.
NATURE MEDICINE (2013)
Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure
Filip K. Swirski et al.
SCIENCE (2013)
Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion
Iara F. Kretzer et al.
CELLULAR ONCOLOGY (2012)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
AMERICAN HEART JOURNAL (2011)
Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease
Joel A. Lardizabal et al.
CARDIOLOGY CLINICS (2011)
The Role of Matrix Metalloproteinases in Atherothrombosis
Daniel F. J. Ketelhuth et al.
CURRENT ATHEROSCLEROSIS REPORTS (2011)
Progress and challenges in translating the biology of atherosclerosis
Peter Libby et al.
NATURE (2011)
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Israel F. Charo et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Macrophage death and defective inflammation resolution in atherosclerosis
Ira Tabas
NATURE REVIEWS IMMUNOLOGY (2010)
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
Paul M. Ridker
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit
Raul C. Maranhao et al.
ATHEROSCLEROSIS (2008)
Low Numbers of FOXP3 Positive Regulatory T Cells Are Present in all Developmental Stages of Human Atherosclerotic Lesions
Onno J. de Boer et al.
PLOS ONE (2007)
Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers
Maria L. N. Dias et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE
KV Pinheiro et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits
SJ Nicholls et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE)
RS Teixeira et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease
VTM Hungria et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide
CJ Valduga et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel
DG Rodrigues et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2002)
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients
RC Maranhao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
The thin-cap fibroatheroma: a type of vulnerable plaque - The major precursor lesion to acute coronary syndromes
FD Kolodgie et al.
CURRENT OPINION IN CARDIOLOGY (2001)
Share Paper
